CNDO Profile
Coronado
Biosciences, Inc. (CNDO) is no longer a publicly traded company. As of
my knowledge cutoff of September 2021, the company was acquired by a
private company, and its stock is no longer listed on any major stock
exchanges.
Coronado Biosciences was a clinical-stage
biopharmaceutical company focused on the development of immunotherapy
products for the treatment of autoimmune diseases and cancer. The
company's lead product candidate was CNDO-109, a biologic therapy that
was being developed for the treatment of autoimmune and inflammatory
diseases such as Crohn's disease and ulcerative colitis.
CNDO-109 was designed to selectively deplete disease-causing immune
cells while leaving healthy immune cells intact. The therapy used a
unique combination of drugs to target and eliminate specific immune
cells, potentially providing a more targeted and effective treatment
option for patients with autoimmune and inflammatory diseases.
However, it appears that the development of CNDO-109 and other product
candidates has been discontinued following the company's acquisition.
As a result, there is no further information available about the
current status of Coronado Biosciences or its product development
|
